BioCentury | Jul 31, 2020
Product Development

Latest Pfizer, BioNTech COVID-19 vaccine commitment will send 120M doses to Japan

BioNTech and Pfizer have agreed to provide Japan with 120 million doses of its COVID-19 vaccine, a week after closing a 100 million dose procurement deal with the U.S. The agreement came as the German...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Fat metabolism enzyme DECR1 as castration-resistant prostate cancer target

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting the β oxidation enzyme DECR1 could treat castration-resistant prostate cancer. In biopsies from prostate cancer patients, DECR1 protein levels were higher after the development of resistance to androgen...
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fifth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the...
BioCentury | Jul 31, 2020
Product Development

Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines

Two more COVID vaccine developers have published non-human primate data suggesting efficacy, bringing the total to five. One of the new papers builds on the case for neutralizing antibodies as key correlates of protection; the...
BioCentury | Jul 31, 2020
Product Development

COVID-19 antibody treatments could be available in September, ahead of vaccines

COVID-19 antibody therapeutics could be authorized as early as September, with vaccines expected to be available later in the fall, a senior government official said Thursday. In addition to updating the countermeasure timeline, the official...
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | Jul 30, 2020
Deals

Data Bytes: how Warp Speed’s deals stack up

Moderna’s total COVID-19 vaccine funding from Operation Warp Speed is now up to $955 million after the company expanded its contract with the Biomedical Advanced Research and Development Authority (BARDA) this week. That gives Moderna...
BioCentury | Jul 29, 2020
Product Development

Moderna’s COVID-19 vaccine protects monkeys without inducing CD8+ T cell responses

Non-human primate data from NIAID and Moderna’s COVID-19 vaccine argue that vaccine-induced neutralizing antibodies alone may be enough to achieve sterilizing immunity, though the findings do not rule out important roles for cytotoxic T cells....
BioCentury | Jul 29, 2020
Product Development

Pfizer lays out two phases of COVID-19 vaccine pricing

Developed countries won’t be charged less than the U.S. for Pfizer and BioNTech’s COVID-19 vaccine, though the U.S. company anticipates recalibrating the price based on value after the pandemic subsides. The pricing comments came Tuesday...
Items per page:
1 - 10 of 9822
BioCentury | Jul 31, 2020
Product Development

Latest Pfizer, BioNTech COVID-19 vaccine commitment will send 120M doses to Japan

BioNTech and Pfizer have agreed to provide Japan with 120 million doses of its COVID-19 vaccine, a week after closing a 100 million dose procurement deal with the U.S. The agreement came as the German...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Fat metabolism enzyme DECR1 as castration-resistant prostate cancer target

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting the β oxidation enzyme DECR1 could treat castration-resistant prostate cancer. In biopsies from prostate cancer patients, DECR1 protein levels were higher after the development of resistance to androgen...
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fifth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the...
BioCentury | Jul 31, 2020
Product Development

Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines

Two more COVID vaccine developers have published non-human primate data suggesting efficacy, bringing the total to five. One of the new papers builds on the case for neutralizing antibodies as key correlates of protection; the...
BioCentury | Jul 31, 2020
Product Development

COVID-19 antibody treatments could be available in September, ahead of vaccines

COVID-19 antibody therapeutics could be authorized as early as September, with vaccines expected to be available later in the fall, a senior government official said Thursday. In addition to updating the countermeasure timeline, the official...
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | Jul 30, 2020
Deals

Data Bytes: how Warp Speed’s deals stack up

Moderna’s total COVID-19 vaccine funding from Operation Warp Speed is now up to $955 million after the company expanded its contract with the Biomedical Advanced Research and Development Authority (BARDA) this week. That gives Moderna...
BioCentury | Jul 29, 2020
Product Development

Moderna’s COVID-19 vaccine protects monkeys without inducing CD8+ T cell responses

Non-human primate data from NIAID and Moderna’s COVID-19 vaccine argue that vaccine-induced neutralizing antibodies alone may be enough to achieve sterilizing immunity, though the findings do not rule out important roles for cytotoxic T cells....
BioCentury | Jul 29, 2020
Product Development

Pfizer lays out two phases of COVID-19 vaccine pricing

Developed countries won’t be charged less than the U.S. for Pfizer and BioNTech’s COVID-19 vaccine, though the U.S. company anticipates recalibrating the price based on value after the pandemic subsides. The pricing comments came Tuesday...
Items per page:
1 - 10 of 9822